Key result
Rituximab infusion was temporally associated with cardiovascular adverse events, including atrial fibrillation and chest pain, in two patients with stage IV non-Hodgkin lymphoma.
Why the study?
Does rituximab infusion cause cardiovascular adverse events in patients with non-Hodgkin lymphoma?
Population
n=2 patients with stage IV non-Hodgkin lymphoma with bone marrow infiltration and peripheral blood…
Design
Case_report
Authors
Loading...
May prompt cardiac monitoring in rituximab recipients with lymphoma; case reports leave causality and incidence open.
Case Report (n=2)
Does rituximab infusion cause cardiovascular adverse events in patients with non-Hodgkin lymphoma?
Rituximab infusion may be associated with cardiovascular adverse events such as atrial fibrillation and chest pain, highlighting the need for careful cardiac assessment in patients with cardiovascular risk factors.
Passalia et al. (2014) conducted a case report in Stage IV non-Hodgkin lymphoma (n=2). Rituximab was evaluated on Cardiovascular adverse events (atrial fibrillation and chest pain). Rituximab infusion was temporally associated with cardiovascular adverse events, including atrial fibrillation and chest pain, in two patients with stage IV non-Hodgkin lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: